New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...
Aclaris Therapeutics announces publication describing properties of ATI-2138
Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...
Clinical trial finds RNA inhibitor effectively reduces 'bad cholesterol' in patients with cardiovascular disease
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
Medscape5d
Tocilizumab: The First Interleukin-6-Receptor Inhibitor
Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL ... a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients ...
EurekAlert!3d
An RNA inhibitor may effectively reduce a high-risk type of cholesterol in patients with cardiovascular disease
Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...
infectiousdiseaseadvisor.com2d
Children With Rheumatic Diseases at Higher Risk for Severe COVID-19 Outcomes
Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.
Armed robbery in Revesby2d
RNA Inhibitor Reduces High-Risk Cholesterol in CVD
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
News Medical on MSN2d
Olpasiran significantly lowers "bad cholesterol" linked to cardiovascular risk
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...
Armed robbery in Revesby2d
RNA Inhibitor May Cut High-Risk Cholesterol in Patients
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according ...
HDAC Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
The Brighterside of News on MSN5d
Revolutionary new cancer treatment destroys tumors in less than 6 days
Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...